As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of NewcelX Ltd. The largest reported stake is League Jinn Sarl's, at 25.3%. 6 filings are on record since November 4, 2025 (Schedule 13D, May 4, 2026).
Sell to companies like NewcelX Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: League Jinn Sarl · Percent: 25.3% · SCHEDULE 13D
- · Holder: Michel Revel · Percent: 20.2% · SCHEDULE 13D
- · Holder: League Jinn Sarl · Percent: 21.6% · SCHEDULE 13G
- · Holder: Ronen Twito · Percent: 6% · SCHEDULE 13D
- · Holder: Clover Wolf Capital - Limited Partnership · Percent: 7.5% · SCHEDULE 13G
NewcelX Ltd. has 6 Schedule 13D or 13G filings on record since 2025-11-04. 4 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| League Jinn Sarl | 25.3% | 1,316,267 | SCHEDULE 13D, 2026-05-04 | 2026-04-27 |
| 20.2% | 940,787 | SCHEDULE 13D, 2025-11-14 | 2025-10-30 | |
| Clover Wolf Capital - Limited Partnership | 7.5% | 343,120 | SCHEDULE 13G, 2025-11-07 | 2025-10-30 |
| 6% | 272,399 | SCHEDULE 13D, 2025-11-13 | 2025-10-30 | |
| Bvf Gp Holdings LLC | 0.6% | 26,942 | SCHEDULE 13G/A, 2025-11-04 | 2025-10-31 |
Holding shares or following this stake? See who's behind NewcelX Ltd. and the warning signs.
Free to see. No signup.
Keep reading
More on NewcelX Ltd. and the records around it.
NewcelX Ltd. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Form D filing May 2026
- Who owns it
Companies that share a holder
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch NewcelX Ltd.
Get an email when NewcelX Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NewcelX Ltd.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NewcelX Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NewcelX Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
League Jinn Sarl
The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person holds all securities of the Issuer for investment purposes only. The Common Shares beneficially owned by the Reporting Person were acquired as follows: 2024 Securities Purchase Agreement On October 9, 2024, NLS Pharmaceutics Ltd. (now known as the Issuer following the Merger (as defined below)), entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the securities purchase agreement, the Issuer agreed to issue and sell to the investors, in a private placement offering, (i) 806,452 Common Shares, and (ii) common share purchase warrants to purchase 806,452 Common Shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The Common Warrants have a term of five years and have an exercise price of $4.25 per share. The Issuer agreed not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the securities purchase agreement closed on October 10, 2024. In connection with this securities purchase agreement, the Reporting Person purchased 207,913 Common Shares and common warrants to purchase 207,913 Common Shares, all with his personal funds. Following the Merger, such Common Shares and common warrants were …The first part of Item 4 of the SCHEDULE 13D filed 2026-05-04; the filing has the rest
Ronen Twito
The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person holds all securities of the Issuer for investment purposes only. The Common Shares beneficially owned by the Reporting Persons were acquired as follows: Merger Transaction On November 4, 2024, NLS Pharmaceutics Ltd. ("NLS") entered into an Agreement and Plan of Merger, as subsequently amended, with Kadimastem Ltd. ("Kadimastem"). The merger (the "Merger") was completed in 2025, pursuant to which NLS Pharmaceutics (Israel) Ltd., a wholly owned subsidiary of NLS, merged with and into Kadimastem, with Kadimastem continuing as the surviving company and a wholly owned subsidiary of NLS. Following the Merger, the combined company was renamed NewcelX, Ltd. ("NewcelX" or the "Issuer"). In connection with the Merger, each outstanding ordinary share of Kadimastem was exchanged for NewcelX Common Shares in a final exchange ratio of 0.706 NLS Common Shares for each Kadimastem ordinary share. As a result of the Merger, the Reporting Person, who served as the Executive Chairman and Chief Executive Officer of Kadimastem, became Executive Chairman and Chief Executive Officer of NewcelX. At the effective time of the Merger, the 349,331 Kadimastem ordinary shares previously beneficially owned by the Reporting Person were converted into 246,508 NewcelX Common Shares pursuant to the exchange ratio, and all 36,690 outstanding restricted stock …The first part of Item 4 of the SCHEDULE 13D filed 2025-11-13; the filing has the rest
Michel Revel
The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person holds all securities of the Issuer for investment purposes only. The Common Shares beneficially owned by the Reporting Person were acquired as follows: 2024 Securities Purchase Agreement On October 9, 2024, NLS Pharmaceutics Ltd. (now known as the Issuer following the Merger (as defined below)), entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the securities purchase agreement, the Issuer agreed to issue and sell to the investors, in a private placement offering, (i) 806,452 Common Shares, and (ii) common share purchase warrants to purchase 806,452 Common Shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The Common Warrants have a term of five years and have an exercise price of $4.25 per share. Pursuant to the securities purchase agreement, the Issuer agreed to grant the investors the right to participate, in the aggregate, in up to fifty percent (50%) of future offerings for one year following the closing of the offering. In addition, the Issuer agreed to not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the securities purchase agreement closed on October 10, 2024. In …The first part of Item 4 of the SCHEDULE 13D filed 2025-11-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-04 | Bvf Gp Holdings LLC | 0.6% | SCHEDULE 13G/A |
| 2025-11-07 | Clover Wolf Capital - Limited Partnership | 7.5% | SCHEDULE 13G |
| 2025-11-13 | League Jinn Sarl | 21.6% | SCHEDULE 13G |
| 2025-11-13 | Ronen Twito | 6% | SCHEDULE 13D |
| 2025-11-14 | Michel Revel | 20.2% | SCHEDULE 13D |
| 2026-05-04 | League Jinn Sarl | 25.3% | SCHEDULE 13D |
Questions about who owns NewcelX Ltd.
Who owns NewcelX Ltd.?
On this page, 4 holders' latest ownership filings report 5% or more of NewcelX Ltd.: League Jinn Sarl (25.3%, Schedule 13D, filed 2026-05-04), Michel Revel (20.2%, Schedule 13D, filed 2025-11-14), Clover Wolf Capital - Limited Partnership (7.5%, Schedule 13G, filed 2025-11-07) and Ronen Twito (6%, Schedule 13D, filed 2025-11-13).
Who are the largest shareholders of NewcelX Ltd.?
By the share each holder's latest filing reports, the largest holders of NewcelX Ltd. on this page are League Jinn Sarl (25.3%), Michel Revel (20.2%) and Clover Wolf Capital - Limited Partnership (7.5%).
When did League Jinn Sarl buy into NewcelX Ltd.?
The filings give report dates, not purchase dates. The earliest filing from League Jinn Sarl on this page is the Schedule 13G, filed 2025-11-13, reporting 21.6%; its latest, Schedule 13D filed 2026-05-04, reports 25.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for NewcelX Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 24, 2026 | Form D, private offering | $2.94M sold | Form D page | Source |
| May 13, 2026 | Form D, private offering | $3.43M sold | Form D page | Source |
| July 10, 2025 | Form D, private offering | $1M sold | Form D page | Source |
| April 14, 2025 | Form D, private offering | $2M sold | Form D page | Source |
| January 22, 2025 | Form D, private offering | $500K sold | Form D page | Source |
NewcelX Ltd.: every filing and event
Tools for this story
Each opens in a new tab, filled in for NewcelX Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.